Website Search
ID 2178

Biochemistry of Alzheimer's disease

Professor Donna Wilcock explains that neurotransmitter hypotheses of Alzheimer's disease are largely unspecific. Nevertheless, glutamate, serotonin, and NPY have elicited interest.
Neurotransmitters – many have been implicated in disease, and it really depends on what paper you read. You could pick a neurotransmitter, and out there somewhere is a paper that shows that that neurotransmitter is affected. Glutamate, we know, is the major neurotransmitter involved in long-term potentiation (LTP), and it’s thought that LTP is the mechanism for formation of memory. So glutamate has really been a big for focus for Alzheimer’s [disease], for obvious reasons, that if we can maybe enhance the glutamate effect, we might enhance memory. But the problem is, if you have too much glutamate, you can actually kill the neuron, because they get overexcited, something called excitotoxicity. We have to be very careful with glutamate, and glutamate is really globally expressed through the brain; it’s one of the major transmitters in the brain, so we have to be careful with that. Another one is serotonin, but serotonin is involved in a lot of behavior (e.g. depression). We know that there are some emotional issues later on in Alzheimer’s disease, in the middle to late stage Alzheimer’s disease. So, treatment at that stage for those patients with antidepressants that would target serotonin does seem to be beneficial for the emotional aspect of the disease, more so than memory. The other neurotransmitter is something called neuropeptide Y (NPY), and this seems to be important for blood flow. If we can increase blood flow in the brain, possibly you would be providing more oxygen and more nutrients to the brain to make it healthier. But really there is no good understanding as far as, is it one population? In Parkinson’s disease, we know that it’s the dopaminergic neurons that are specifically affected. It’s a very small part of the brain, and so trying to regenerate those or put back that neurotransmitter is really a very clear goal in Parkinson’s disease, but in Alzheimer’s disease, it’s not that clear cut.
alzheimer, neurotransmitter, biochemical, biochemistry, glutamate, serotonin, npy, dopaminergic, donna, wilcock
Creative Commons License This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Related content:

2227. Alzheimer's disease
An overview of Alzheimer's disease-related content on Genes to Cognition Online.
1392. Biochemistry of Depression
Doctor Jon Lieberman discusses three neurotransmitters that have been associated with depression - dopamine, serotonin, and norepinephrine.
2356. Biochemistry of Bipolar Disorder
Doctor Ellen Leibenluft discusses some of the biochemicals that have been associated with bipolar disorder, including dopamine, serotonin, and glutamate.
2164. Biochemistry of ADHD - serotonin
Professor Philip Shaw discusses the relationship between serotonin and ADHD.
2188. Early-onset Alzheimer's disease, 30-65
Professor Donna Wilcock discusses early-onset Alzheimer's disease, which can reach an advanced stage by the age of 50 or 60 years.
2183. Alzheimer's disease statistics - prevalence and age
Professor Donna Wilcock discusses Alzheimer's disease in the light of increasing prevalence as the population ages.
1439. Biochemicals - Excitation and Inhibition
Doctor Josh Dubnau explains that the genes active in different neurons can make them excitatory (e.g. glutamate) or inhibitory (e.g. GABA). These neurotransmitters are critical to learning.
2186. Alzheimer's disease - clinical testing
Professor Donna Wilcock explains that Alzheimer's disease is diagnosed clinically by a battery of tests that can take a full day to administer.
2080. Biochemistry of depression
Serotonin is the biochemical most commonly associated with depression. Professor Wayne Drevets discusses other systems including norepinephrine, glutamate, and dopamine.
2172. Amyloid plaques
Professor Donna Wilcock describes amyloid plaques as clumps of protein in the brain that are one of the three hallmarks of Alzheimer's disease.
Cold Spring Harbor Laboratory
CSHL HomeAbout CSHLResearchEducationPublic EventsNewsstandPartner With UsGiving